咪达普利和厄贝沙坦对早期自发性高血压大鼠凝血和纤溶系统的影响

Effects of Imidapril and Irbesartan on Coagulative and Fibrinolytic System in Early Spontaneously Hypertensive Rats

目的观察咪达普利 (imidapril)和厄贝沙坦 (irbesartan)在降压同时 ,对早期雄性自发性高血压大鼠 (SHR)血浆凝血酶原时间 (PT)、纤维蛋白原含量 (FIB)、组织型纤溶酶原激活物活性 (t PA :A)、纤溶酶原激活物抑制剂活性 (PAI:A)和α2 纤溶酶抑制物活性 (α2 PI:A)的影响。方法 1 5周龄雄性SHR 30只随机分为三组 ,咪达普利组给含im idapril的水 3mg·kg- 1 ·d- 1 ;厄贝沙坦组给含irbesartan的水 50mg·kg- 1 ·d- 1 ;SHR对照组和同龄雄性WistarKyoto(WKY)正常血压对照组 1 0只以等量蒸馏水代替 ;采用一期法检测血浆PT ,采用凝血酶法检测血浆FIB ,采用发色底物法检测血浆t PA :A、PAI :A和α2 PI :A。结果 与WKY组比较 ,SHR组血浆FIB显著增高 (P <0 0 1 ) ,α2 PI:A显著降低 (P <0 0 1 )。咪达普利组和厄贝沙坦组经过三个月治疗血压明显降低 (P <0 0 1 ) ,FIB显著降低 (P <0 0 1 ) ,α2 PI :A显著增高 (P <0 0 1 )。结论 (1 )早期雄性SHR血管内凝血与纤溶并存 ,提示早期雄性SHR已处于慢性过代偿型弥散性血管内凝血 (DIC)凝溶期 ,因而有血栓栓塞和 /或出血的危险性 ;(2 )咪达普利和厄贝沙坦对早期雄性SHR的干预能逆转SHR慢性隐性DIC所致的血栓前状态 (PTS)和动脉粥样硬化 (AS) ,改善其已受?

Objective\ To survey the effects of imidarpril and irbesartan on plasma prothrombin time(PT),fibrinogen(FIB), tissue type plasminogen activator activity(t\|PA:A), plasminogen activator inhibitor ativity(PAI:A) and α 2 plasmin inhibitor ativity(α 2 PI:A) in spontaneously hypertensive rats (SHR).\ Methods\ Thirty SHRs(15 weeks old male) were divided into three groups, imidapril(3 mg·kg -1 ·d -1 ), irbesartan(50 mg·kg -1 ·d -1 ) or equal volume of distilled water were adminstered by drinking in three group of SHR for three months.\ Ten age matched male Wistar rats were received equal volume of distilled water by drinking as another control.\ Plasma PT,FIB,t PA:A,PAI:A,α 2 PI:A were determined before and after treatment.\ Results\ After three months treatment of imidapril and irbesartan, the blood pressure(BP) in SHRs were significantly decreased( P< 0 01).\ Compared with the control,the treatmental group of SHR had decreased in FIB and increased in α 2 PI:A level,but no changed of PT,t PA:A,and PAI:A were found.\ Conclusion\ The changes of intravascular coagulation and fibrinolysis indicate that a kind of chronic disseminated intravascular coagulation(DIC) status existed in SHR during the early period.\ The intervention of imidapril and irbesartan could improve the impaired coagulative and fibriolytic system.